Planatome, a medical technology company advancing surgical performance through its patented nano-polishing platform, originally adapted from semiconductor manufacturing, today announced a strategic leadership transition and appointment of two seasoned board members designed to accelerate innovation, deepen market penetration, and drive adoption of its technology within the MedTech sector.  

Keith Jeffcoat, who has served as Planatome’s Chief Technology Officer, has been promoted to President and Chief Innovation Officer. Jeffcoat’s new role reflects the company’s focus on placing innovation at the core of its growth strategy and underscores the importance of leveraging his deep expertise in R&D, executive leadership, and strategy. Jeffcoat stated, “It’s a privilege to serve in executive leadership alongside such visionary minds, where every product we launch isn’t just technological innovation—it’s impact. There’s no greater reward than knowing our work makes a meaningful difference in the lives of patients every day.” Jeffcoat brings over two decades of experience across startups and global MedTech companies such as Johnson & Johnson and Merz Pharma. His new role places innovation, product excellence, and licensing opportunities at the forefront of Planatome’s strategy, enhancing the company’s impact through next-generation surgical technologies. 

As part of this evolution, Bill Fender will transition to serve on the company’s Executive Board. About his role, Fender stated, “I’m excited to further establish and expand the board’s influence while still lending my MedTech experience to guide the company’s strategic initiatives and relationships.” Fender, a veteran executive with over 30 years in the medical device industry, including key roles at Johnson & Johnson and Ulthera, was a key architect of Planatome’s foundation and has helped bring its technology to the forefront of surgical instrument performance.  

Joining Fender on the Executive Board is Matt Likens, a respected MedTech leader and former CEO of GT Medical Technologies and Ulthera.  Matt expressed strong support, stating, “I’ve had the pleasure of working with both Bill and Keith over the years. Their respective skills and shared commitment to innovation uniquely position Planatome for accelerated growth, and I’m excited to help guide strategic initiatives and develop key relationships.” 

“Keith’s expanded leadership role capitalizes on his proven ability to drive technical excellence and transformative innovation,” said Tim Tobin, CEO of Planatome, who further added, “Drawing upon the vast industry and start-up experience of Matt and Bill will be instrumental to expand the reach of our platform across additional medical and other industry applications.” 

With a reinforced leadership team and an expanded Executive Board, Planatome is actively collaborating with leading medical device companies to deploy its patented nano-polishing technology. These engagements foster strategic partnerships and licensing agreements, which accelerate Planatome’s mission of enhancing surgical performance and improving patient outcomes.